AstraZeneca announced that the Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) as monotherapy for use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who are postmenopausal and have not received previous endocrine therapy.
{iframe}http://www.empr.com/news/fulvestrant-breast-cancer-monotherapy-her2-hr-postmenopausal/article/684553/{/iframe}